Table 4. Comparison of patients treated with breast conserving treatment with either exclusive/preoperative radiotherapy or postoperative radiotherapy.
|
Exclusive or preoperative radiotherapy (N=168)a
|
Postoperative radiotherapy (N=308)
|
||||
|---|---|---|---|---|---|
| Total | N | % | N | % | P |
| Menopause (DM=0) | 0.44 | ||||
| No | 121 | 72 | 232 | 75 | |
| Yes | 47 | 28 | 76 | 25 | |
| Clinical T stage (DM=0) | 0.03 | ||||
| T2 | 129 | 77 | 262 | 85 | |
| T3 | 39 | 23 | 46 | 15 | |
| Clinical N stage (DM=0) | 0.21 | ||||
| N0 | 105 | 63 | 210 | 68 | |
| N1 | 63 | 37 | 98 | 32 | |
| Histological type (DM=0) | <10−3 | ||||
| Ductal | 142 | 85 | 292 | 95 | |
| Lobular | 26 | 15 | 16 | 5 | |
| Clinical response to primary chemotherapy | <10−3 | ||||
| ⩾50% | 104 | 63 | 239 | 78 | |
| <50% | 60 | 37 | 67 | 22 | |
| Hormonal receptors (DM=71) | 0.24 | ||||
| ER+ and/or PR+ | 99 | 68 | 192 | 74 | |
| ER−/PR− | 46 | 32 | 68 | 26 | |
DM=data missing; ER=estradiol receptor; HR=hormonal receptor; PR=progesterone receptor.
a
53 preoperative radiotherapy and 115 exclusive radiotherapy.